Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation reports developments in synthetic biology built around its silicon-based DNA synthesis platform. Company updates cover synthetic DNA tools and services for diagnostics, therapeutics, industrial, agriculture and research markets, including oligos, genes, proteins, libraries, characterization data, antibody discovery solutions and NGS workflow tools.
Recurring announcements include fiscal results, business updates, product launches such as expanded clonal gene capabilities and library preparation kits, antibody discovery licensing, investor presentations and Nasdaq inducement equity awards for new employees.
Twist Bioscience (NASDAQ: TWST) announced preliminary, unaudited revenue for the first quarter of fiscal 2026, the quarter ended December 31, 2025. Finalized financial results will be released before market open on February 2, 2026.
The company will host a conference call and live audio webcast for analysts and investors on February 2, 2026 at 8:00 a.m. Eastern Time. Webcast access, registration for telephone participation (which provides a dial-in number and unique PIN), and the replay (available for two weeks) are available through the Investor Relations section of the company website.
Twist Bioscience (NASDAQ: TWST) announced that CEO and co-founder Emily M. Leproust, Ph.D. will present at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026 at 2:15 pm Pacific Time in San Francisco.
The presentation will be webcast live and available via the company's Investor Calendar on the investor relations website, with a replay archived for 30 days after the live event.
Twist Bioscience (NASDAQ: TWST) launched research-grade Plasmid DNA Preps to support preclinical nucleic acid therapeutics research, including antisense and gene therapies. The offering includes animal origin-free (AOF) and transfection-grade preps, low/endotoxin options, and target yields for prep sizes from 4µg to 10µg. Twist states turnaround for Express Genes starts at four business days. AOF products are available with TSE and BSE certificates to verify quality and meet common preclinical transfer requirements.
Twist Bioscience (NASDAQ: TWST) announced its fiscal 2025 fourth quarter and full year financial results for the period ended September 30, 2025.
The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time on November 14, 2025 to discuss results and business updates. The webcast and replay are available via the Investor Relations Events and Presentations page at investors.twistbioscience.com.
Telephone participants must register on the investor site to receive a dial-in number and unique PIN; callers are advised to dial in 15 minutes early. The webcast replay will be available for two weeks.
Twist Bioscience (NASDAQ: TWST) announced that CEO and co‑founder Emily M. Leproust, Ph.D. and CFO Adam Laponis will participate in a fireside chat at the 7th Annual Wolfe Research Healthcare Conference on Monday, November 17, 2025 at 3:20 PM ET in New York City.
The session will be webcast live and available via the company's Investor Calendar on its investor relations website. A replay will be archived for 30 days after the live event.
Twist Bioscience (NASDAQ: TWST) granted a total of 139,569 equity awards as inducements to 41 newly hired employees: 91,441 restricted stock units (RSUs) and up to 48,128 performance stock units (PSUs). RSU vesting schedules vary by employee, with portions vesting over 48 months — either 25% at the one-year anniversary then 1/16 quarterly, or 1/16 quarterly from the Vesting Commencement Date — subject to continued service.
Up to 48,128 PSUs vest based on performance metrics set by the Compensation Committee, to be achieved no later than the end of the 2027 fiscal year, with payout range from 50% to 140% of target, subject to service-based vesting conditions.
Twist Bioscience (NASDAQ: TWST) will report fiscal 2025 fourth quarter and full year results for the period ended September 30, 2025 on Friday, November 14, 2025 before market open. A conference call and live audio webcast for analysts and investors is scheduled for 8:00 AM ET the same day to review results and provide a business update.
The press release with financial results will be posted in the company Investor Relations section at www.twistbioscience.com prior to the call. Telephone participants must register on the Investor Relations site to receive a dial-in number and unique PIN. Attendees are encouraged to dial in 15 minutes early. A webcast replay will be available for two weeks.
Twist Bioscience (NASDAQ: TWST) and Element Biosciences launched the Trinity Freestyle Fast Hybridization workflow for Element’s AVITI and AVITI24 sequencing platforms on October 6, 2025. The end-to-end solution enables sample-to-sequencer runs in as little as five hours and uses a rapid 1-hour hybridization with on-flow cell enrichment to remove binding, wash, amplification and pooling steps. Under an expanded agreement, Twist gains exclusive access to the Trinity Freestyle workflow for use with Twist’s library prep kits, including Enzymatic Fragmentation Kit 2.0 and FlexPrep UHT. The integration aims to provide compatibility with P5/P7-adapted libraries and Twist unique dual indexes, with expanded support subject to further validation.
Twist Bioscience (NASDAQ: TWST) on October 2, 2025 announced co-authorship of a peer‑reviewed paper in Science titled “Strengthening nucleic acid biosecurity screening against generative protein design tools.”
The study, led by Microsoft with industry and scientific partners including the International Gene Synthesis Consortium, ran a red‑teaming exercise showing some AI‑designed protein variants could evade standard biosecurity screening. Twist and collaborators used the results to develop patches and new screening strategies to improve detection of engineered sequences. The paper emphasizes iterative improvement, cross‑industry collaboration, and foresight to mitigate AI‑related biosecurity risks while noting the tested sequences were digital and their pathogenicity if manufactured is unknown.
Twist Bioscience (NASDAQ: TWST), a mid-cap biotech company, has announced upcoming presentations at two major healthcare conferences. CEO and co-founder Emily M. Leproust, Ph.D. will present at the Baird 2025 Global Healthcare Conference on September 9, 2025, at 9:40 am ET in New York City.
Additionally, the company will participate in one-on-one meetings at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10, 2025. Both presentations will be accessible via webcast through the company's investor relations website, with replays available for 30 days after the events.